# A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

> **NCT07228247** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hutchmed** · enrollment: 147 (estimated)

## Conditions studied

- Solid Tumors, Adult

## Interventions

- **DRUG:** HMPL-A251
- **DRUG:** HMPL-A251

## Key facts

- **NCT ID:** NCT07228247
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228247, "A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07228247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*